Integrating immunotherapy in the treatment of resectable gastric cancer: Are we on the right track?

Long et al.¹ evaluated neoadjuvant (NAT) cadonilimab plus FLOT chemotherapy (ChT) in locally advanced gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma, showing a pathological complete response (pCR) rate of 21.1% and an R0 resection rate of 100%. These findings align with other perioperative immunotherapy trials, although challenges remain in optimizing event-free survival (EFS).